Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
about
The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision makingEstrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapyGenetic variation: effect on prostate cancer.Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma.ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancerInhibition of constitutive aryl hydrocarbon receptor (AhR) signaling attenuates androgen independent signaling and growth in (C4-2) prostate cancer cells.Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Germline pharmacogenetics of paclitaxel for cancer treatment.Metabolism of the taxanes including nab-paclitaxel.Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy.Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.Treatment regimens of classical and newer taxanes.Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.Enhanced anti-tumor efficacy and mechanisms associated with docetaxel-piperine combination- in vitro and in vivo investigation using a taxane-resistant prostate cancer model.A feasibility and safety study of concurrent chemotherapy based on genetic testing in patients with high-risk salivary gland tumors: Preliminary results.
P2860
Q27025062-E0946137-E2AB-4683-81E8-9F724C240103Q34622545-D56EBB84-CFF3-40C2-BF69-312EFF6CED68Q34663656-F7C2D7B6-9452-435B-888E-12743BD92893Q35781414-D0333573-3452-4035-B8D1-9A459C30B3A5Q35823740-64F35A47-CA19-412D-9168-AE0CEC499309Q35925260-A7F52054-5BD4-4376-824C-307C4F45280BQ36873039-BA9FAD29-52D7-4E4C-9E63-DB481BD4D4DAQ37013311-728D971A-FDED-4997-AA1C-291772C4B81FQ37055326-411C5EA4-1B26-4578-A6BD-C949F477B033Q37684533-D4CF8365-2224-4E9E-8E07-39CDC0339CCCQ38120289-929D2D85-8332-475E-A07D-EF402E44A79BQ38267987-126F36BE-B89B-41E3-9D0D-06B500C7F9F7Q38305705-0625E78C-6768-43BF-931E-5DEFF4FAF070Q38533459-60571C03-0BFB-4764-882C-863661463EEDQ38641136-E72CCAA4-83E4-4D32-B0A5-EFB4A7D50CA3Q49049921-0FD1A272-050C-43F5-87CF-7AEDB9744F48Q49520967-B5EB2CA4-142A-461F-B417-F2C04A2B4F7CQ55129591-FB66FED5-7A3F-499C-ACB5-ACDD0E6D9241
P2860
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cytochrome 450 1B1 (CYP1B1) po ...... ostate Cancer (CRPC) patients.
@ast
Cytochrome 450 1B1 (CYP1B1) po ...... ostate Cancer (CRPC) patients.
@en
type
label
Cytochrome 450 1B1 (CYP1B1) po ...... ostate Cancer (CRPC) patients.
@ast
Cytochrome 450 1B1 (CYP1B1) po ...... ostate Cancer (CRPC) patients.
@en
prefLabel
Cytochrome 450 1B1 (CYP1B1) po ...... ostate Cancer (CRPC) patients.
@ast
Cytochrome 450 1B1 (CYP1B1) po ...... ostate Cancer (CRPC) patients.
@en
P2093
P2860
P50
P356
P1433
P1476
Cytochrome 450 1B1 (CYP1B1) po ...... rostate Cancer (CRPC) patients
@en
P2093
Aldo Chioni
Cinzia Orlandini
Claudia Cianci
Douglas K Price
Ilaria Pastina
Sergio Ricci
Tristan M Sissung
William D Figg
P2860
P2888
P356
10.1186/1471-2407-10-511
P407
P577
2010-09-27T00:00:00Z
P5875
P6179
1049101761